Clinical LC-MS/MS applications have been in routine service for just over 20 years. The introduction of electrospray ionisation first allowed development of new-born screening methods, but it was not until the start of the new millennium when routine applications for immunosuppressant drugs and then steroids began to emerge. Method development was driven by the increased sensitivity and specificity offered by LC-MS/MS over existing immunoassay (IA) and HPLC methods. Compared to HPLC, the new LC-MS/MS methods were faster, sample preparation was often simpler and drugs such as ciclosporin which have no chromophores could be measured for the first time using chromatographic methods. Immunosuppressant drugs continue to be measured by LC-MS/MS in the larger transplant centres and methods have now evolved to measure finger prick samples collected by the patient at home. This is proving to be a useful strategy in the COVID era with many clinics being performed remotely.¹

中文翻译：

---

LC-MS/MS 前 20 年：个人观点

临床 LC-MS/MS 应用已在常规服务中使用了 20 多年。电喷雾电离的引入首先允许开发新生儿筛查方法，但直到新千年开始，免疫抑制剂和类固醇的常规应用才开始出现。LC-MS/MS 比现有免疫测定 (IA) 和 HPLC 方法提高了灵敏度和特异性，推动了方法开发。与 HPLC 相比，新的 LC-MS/MS 方法速度更快，样品制备通常更简单，并且首次可以使用色谱方法测量没有发色团的药物，例如环孢素。在较大的移植中心，免疫抑制剂药物继续通过 LC-MS/MS 进行测量，并且方法现在已经发展到测量患者在家中采集的手指刺样本。事实证明，这在 COVID 时代是一种有用的策略，许多诊所都是远程执行的。¹